iNtRON Biotechnology, Inc.
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
iNtRON Bio, files Two Patent Applications for IMPA™ Platform-Based Gene Editing Technology 2025-08-26 21:00
iNtRON Bio, Demonstrated Toxin-Neutralizing Effect of IMPA™ Phage Engineering Technology in Colorectal Cancer Model and Completed the US Patent Application 2025-08-05 20:00
[iNtRON] Files U.S. Patent for Three Novel Endolysin-Based Drug Candidates Targeting Gram-Negative Bacteria 2025-07-02 20:00
iNtRON Seeks a Strategic Partner to Explore the Promising Market for MRSA Decolonization 2025-05-13 20:00
iNtRON, Development of PHAGERIA® Anti-Cancer Candidate with Enhanced Antimicrobial Activity by Robot Bacteriophage platform technology 2024-02-15 11:37
iNtRON, Executes Evaluation License and Option Agreement for SAL200 2023-10-31 12:20
iNtRON identifies Prophage and Jamphage in the Pancreatic cancer related Microbiome 2023-05-30 10:15
iNtRON confirms cancer-controlling effect of PHAGERIA® drug candidate in the organoid model. 2023-04-04 10:33
iNtRON has confirmed the efficacy of BAL200, a novel endolysin biologic for Inhalational Anthrax 2023-01-26 10:34
iNtRON is finalizing the SAL200 Tech Transfer 2023-01-12 09:34
iNtRON developed advanced bacteriophage engineering platform technology based on modified random mutagenesis 2022-10-18 11:56
iNtRON developed New CRISPR/Cas technology specific for Bacteriophage as PHAGERUS® Platform 2022-08-10 09:00
iNtRON Confirms Efficacy of CDL200 Against CDI Clinical Isolates 2022-07-12 10:06
iNtRON to Seek a New Clinical Partner for SAL200 Endolysin 2022-06-28 21:00
iNtRON Completes GLP-TOX Studies of BAL200 2022-06-07 09:00
iNtRON Biotechnology, Inc., Launches New Website 2022-05-09 21:00
1